[Changes in the clinical and immunological indices of patients with disseminated sclerosis being treated with prednisolone].
The authors examined clinically and immunologically 60 patients with multiple sclerosis. One group (30 patients) received prednisolone in the complex treatment while the second group (30 patients) received only complex treatment. A control group of 20 healthy persons was examined. Patients of the first group showed marked neurological and immunological disorders which is considered as a complication due to the empiric prednisolone doses.